Nebicapone (BIA 3-202) is a reversible catechol-O-methyltransferase (COMT) inhibitor that is metabolized primarily via glucuronidation. Nebicapone is mainly a peripherally acting inhibitor. By inhibiting COMT and reducing the bioconversion of L-DOPA to 3-O-methyl-DOPA, Nebicapone may be utilized in the research/study of Parkinson's disease (PD).

Physicochemical Properties

Molecular Formula	C14H11NO5
Molecular Weight	273.244
Exact Mass	273.064
CAS #	274925-86-9
PubChem CID	9838389
Appearance	Light yellow to yellow solid powder
LogP	2.954
Hydrogen Bond Donor Count	2
Hydrogen Bond Acceptor Count	5
Rotatable Bond Count	3
Heavy Atom Count	20
Complexity	361
Defined Atom Stereocenter Count	0
InChi Key	MRFOLGFFTUGAEB-UHFFFAOYSA-N
InChi Code	InChI=1S/C14H11NO5/c16-12(6-9-4-2-1-3-5-9)10-7-11(15(19)20)14(18)13(17)8-10/h1-5,7-8,17-18H,6H2
Chemical Name	1-(3,4-dihydroxy-5-nitrophenyl)-2-phenylethanone
Synonyms	BIA 3202; BIA-3202; Nebicapone
HS Tariff Code	2934.99.9001
Storage	Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage.
Shipping Condition	Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

Biological Activity

References	[1]. Human metabolism of nebicapone (BIA 3-202), a novel catechol-o-methyltransferase inhibitor: characterization of in vitro glucuronidation. Drug Metab Dispos. 2006 Nov;34(11):1856-62.
Additional Infomation	Nebicapone is under investigation in clinical trial NCT03097211 (Effect of BIA 6-512 at Steady-state on the Levodopa Pharmacokinetics With a Single-dose of Levodopa/Benserazide 200/50 mg or With a Single-dose of Levodopa/Benserazide 200/50 mg Plus a Single-dose of Nebicapone 150 mg).

Solubility Data

Solubility (In Vitro)

DMSO : ≥ 100 mg/mL (~365.98 mM)

Solubility (In Vivo)

Solubility in Formulation 1: ≥ 2.5 mg/mL (9.15 mM) (saturation unknown) in 10% DMSO + 40% PEG300 +5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 + to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution.  (Please use freshly prepared in vivo formulations for optimal results.)

Preparing Stock Solutions		1 mg	5 mg	10 mg
	1 mM	3.6598 mL	18.2989 mL	36.5979 mL
	5 mM	0.7320 mL	3.6598 mL	7.3196 mL
	10 mM	0.3660 mL	1.8299 mL	3.6598 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.